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SUMMARY 
Lymphatic vasculature is crucial for metastasis in triple-negative breast cancer 
(TNBC); however, cellular and molecular drivers controlling lymphovascular 
metastasis are poorly understood. We define a macrophage-dependent signaling 
cascade that facilitates metastasis through lymphovascular remodeling. TNBC cells 
instigate mRNA changes in macrophages resulting in β4 integrin-dependent 
adhesion to the lymphovasculature. β4 integrin retains macrophages proximal to 
lymphatic endothelial cells (LECs), where release of TGFβ1 drives LEC contraction 
via RhoA activation. Macrophages promote gross architectural changes to 
lymphovasculature by increasing dilation, hyperpermeability and disorganization. 
TGFβ1 drives β4 integrin clustering at the macrophage plasma membrane further 
promoting macrophage adhesion, demonstrating dual functionality of TGFβ1 
signaling in this context.  β4 integrin expressing macrophages were identified in 
human breast tumors and a combination of vascular-remodeling macrophage gene 
signature and TGFβ signaling scores correlates with metastasis. We postulate that 
future clinical strategies for patients with TNBC should target crosstalk between β4 
integrin and TGFβ1.  
 
Key Words: Lymphovasculature, macrophages, cancer, remodeling, adhesion, 
α6β4 integrin, TGFβ1, RhoA. 
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INTRODUCTION 
Tumor cells establish complex interactions with cells within their microenvironment 
that determine malignancy progression (Balkwill et al., 2012). Tumor cell 
dissemination can occur through blood or lymphovasculature, however targeting 
blood vasculature has limited clinical efficacy when lymphatic dissemination is 
prevalent (Wong and Hynes, 2006). 
Breast cancer is divided into subtypes based on histopathological features and gene 
signatures (Gazinska et al., 2013).Triple-negative breast cancer (TNBC) is 
characterized by a lack of druggable targets, is a highly metastatic and associated 
with dismal prognosis (Gazinska et al., 2013, Dent et al., 2007). The prognostic 
significance of lymphangiogenesis in TNBC is under debate. However, invasion into 
lymphatic vessels correlates with poor prognosis suggesting that targeting existing 
lymphatic vessel network could provide an effective treatment strategy (Choi et al., 
2005, Mohammed et al., 2011, Mohammed et al., 2007, Liu et al., 2009).  
The relationship between tumor and immune cells is often bidirectional and involves 
both tumor-promoting and antagonizing mechanisms (Pollard, 2004, Quail and 
Joyce, 2013). Among innate immune cells, macrophages have been implicated in 
the promotion of tumor progression and, in particular, breast cancer metastasis 
(Condeelis and Pollard, 2006, Kitamura et al., 2015, Pollard, 2004, Harney et al., 
2015). However, it remains unclear how certain subsets of tumor-associated 
macrophages (TAMs) influence breast cancer metastasis spatially, temporally and at 
a molecular level. 
The integrin family  are adhesion receptors of paramount importance for immune cell 
adhesion and migration during inflammatory processes (Evans et al., 2009). Their 
ability to form adhesive contacts is regulated by soluble factors, as part of the 
chemoattractant-adhesion crosstalk that causes a combination of changes in integrin 
conformation and clustering on the plasma membrane (PM) that regulate 
downstream signaling (Hynes, 2002). In malignancy, many integrins common in 
epithelial cells are also present in solid tumors and some, such as αvβ3 and α5β1 
are specifically upregulated in cancer (Desgrosellier and Cheresh, 2010). Tumor-
expressed integrins affect tumor cell migration, proliferation, survival and anchorage 
to the extracellular matrix. Endothelial cell-expressed integrins are implicated in 
angiogenesis, lymphangiogenesis and vascular remodeling (Avraamides et al., 
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2008). While the importance of integrins with respect to maintaining a pro-tumoral 
immune microenvironment in solid tumors is not well defined, in chronic lymphocytic 
leukemia, impaired integrin signaling in non-leukemic T cells changes the immune 
microenvironment to be more immunosuppressive which may facilitate malignancy 
progression (Ramsay et al., 2013).  
We seek to identify the role of tumor-associated macrophages (TAMs) in regulating 
existing lymphovasculature in TNBC where lymphatic dissemination is not a direct 
result of lymphangiogenesis.  
We propose that macrophages have an important role in controlling established 
tumoral lymphatic networks in TNBC, and that lymphatic dissemination of cancer 
cells is facilitated by a cascade of signaling events initiated by integrin-mediated 
adhesion of macrophages at the sites of lymphatic vessels. 
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RESULTS 
Lymphovascular macrophages in TNBC mouse models are retained through binding 
of β4 integrin to laminin-5. To identify endogenous macrophages with respect to 
lymphatic vasculature in murine TNBC tumors we scored F4/80+Tie2+ macrophages 
within podoplanin+ lymphovasculature across multiple fields of view (FOV) from 
4T1.2 and BLG-Cre;Brca1f/f,p53+/-  TNBC models (Molyneux et al., 2010, Melchor et 
al., 2014) (Figure 1 A and B). The Tie2-expressing macrophage (TEM) subset is 
associated with angiogenesis and lymphatic development (De Palma et al., 2007, De 
Palma et al., 2005, Gordon et al., 2010). Lymphovascular associated macrophages 
expressing Tie2 have recently been reported in a small breast cancer cohort (Bron et 
al., 2016). In 4T1.2 tumors we found a mean value of 6.3 F4/80+Tie2+ macrophages 
within podoplanin+ vasculature (versus 1.7 in podoplanin- regions) per FOV. In BLG-
Cre;Brca1f/f,p53+/-  tumors we observed 8.8 F4/80+Tie2+ macrophages in 
podoplanin+ vasculature (versus 2.0 in podoplanin-regions) per FOV. Therefore 
F4/80+Tie2+ macrophages are enriched in lymphovascular regions in murine TNBC 
models.  
The β4 integrin subunit is a transmembrane glycoprotein associating exclusively with 
6 integrin subunit. 6β4 integrin is expressed predominantly on epithelial and 
endothelial cells and binds to laminins to form adhesion complexes, 
hemidesmosomes (Stewart and O'Connor, 2015). Microarray analysis of 
endogenous macrophages co-cultured with 4T1.2 tumor cells showed mean 1.8-fold 
upregulation of β4 integrin at the RNA level compared with non-educated 
endogenous macrophages and that the RAW264.7 macrophage cell line similarly 
exhibited mean 1.58-fold increase in β4 integrin levels compared to endogenous 
macrophages (Figure 1 C and data published in Array Express: MTAB-4064).  
4T1.2 tumors were excised and disaggregated at day 10. Within 4T1.2 tumors we 
defined a population of macrophages as CD45+Ly6G-CD31-CD11b+Tie2+β4 integrin+ 
(Figure 1 D). 
The influence of tumor education on macrophage adhesion to β4 integrin ligand, 
laminin-5, was investigated. Tumor-educated endogenous macrophages displayed 
increased adhesion to laminin-5 (30.7 ± 7.2% to 81.7 ± 13.2 % adherent cells on 0.5 
M laminin-5; Figure 1 E). As laminin-5 is reportedly localized in areas with high 
blood vessel density we investigated if laminin-5 was also in areas of 
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lymphovasculature. 4T1.2 tumor tissue analysis showed laminin-5 furnished around 
podoplanin+ lymphovasculature (Figure 1 F). In addition we observed macrophages 
expressing 6β4integrin in lymphovascular regions (Figure 1G). 
To study β4 expression in vivo we used primary 4T1.2 tumor sections stained with 
Lyve1-Cy3 and β4 integrin-Cy5. Tissues were imaged using a protocol involving 
laser photobleaching to remove autofluorescence. Our methodology reveals β4 
integrin throughout the tumor; however within lymphatic vessels there is differential 
distribution of β4 integrin with relative increases in β4 accumulation observed in 
lymphovascular areas proximal to Lyve1+ lymphatic endothelial cells (LECs) (white 
arrow). Additionally there were lymphovascular areas with increased localized 
Pearson coefficient suggesting LECs and β4 integrin-expressing macrophages in 
close contact (blue arrow) (Figure 1 H) (mean colocalization coefficient of 4.094 ± 
0.8146). 
 
TAMs drive disorganized and hyperpermeable lymphatic architecture and contact 
between macrophages and LECs results in RhoA-dependent contraction. We used  
a mammary image window (MIW) subcutaneously implanted over a 4T1.2-mCherry 
tumor (Kedrin et al., 2008) (Figure 2A). Injection of 76kDa dextran-FITC allowed 
visualization of lymphatic vasculature. Using multiphoton microscopy we observed 
that within the tumor, lymphatic vessels leaked dextran dye across the FOV (left 
panel) suggesting high levels of vessel permeability, however in more distal regions, 
lymphatic vessels had a distinct structure and 4T1.2-mCherry intra-lymphatic tumor 
cells could be seen within vessels, suggesting ongoing metastasis (middle and right 
panel respectively). To understand how increasing tumor-associated macrophages 
could phenotypically influence lymphatic vasculature we studied permeability of 
lymphatic vessels from 4T1.2 tumor-bearing mice given intermittent bolus of 
RAW264.7 macrophages during tumor development. Both RAW264.7 macrophages 
and the 4T1.2 tumor line are derived from a BALB/c genetic background allowing us 
to investigate effects of elevated macrophage numbers on tumor progression in vivo 
using a syngeneic model of TNBC.  
To quantify lymphatic vessel permeability in vivo we adapted a protocol previously 
used in angiogenesis studies (Finsterbusch et al., 2014). Using a subcutaneous 
injection of Evans Blue dye, we quantified permeability of the tumoral lymphatics. 
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Tumors with elevated macrophages contained hyperpermeable lymphatic vessels 
with an increase in mean OD per g from 0.7812 ± 0.2956 to 2.290 ± 0.5160 when 
compared to PBS-treated control, suggesting a facilitated pathway between the 
primary tumor and lymphatic vasculature (Figure 2 B). 
To understand effects of elevated macrophages on tumoral lymphatic vessel 
architecture we stained tumour sections from mice treated with PBS or RAW264.7 
macrophages with the lymphatic vessel markers, Lyve1 and podoplanin (Figure 2 C 
and SI 1 A&B) demonstrating both lymphatic markers gave a similar staining 
distribution. Typical sections from PBS treated mice showed small well-formed 
vessels towards the tumor periphery or within the peri-tumoral areas with a mean 
diameter of 13.66 m ± 1.295. This was in contrast to RAW264.7 treated mice that 
had larger vessels with a mean diameter of 48.00 m ± 6.065 indicating increased 
vessel dilation (SI 1 C).  
To quantify changes in lymphatic architecture in tumors with elevated levels of 
macrophages we blindly scored lymphovasculature for disorganization based on the 
following criteria. Smaller vessels with a clear lumen were given low scores (0 and 1) 
compared to larger disorganized vessels with unclear borders (2 and 3). PBS treated 
tumors had a mean disorganization score of 0.25 ± 0.16 and 1.6 ± 0.33 compared to 
1.8 ± 0.29 and 2.5 ± 0.17 for tumors treated with RAW264.7 macrophages (Figure 2 
C).  
To further investigate whether macrophages were sufficient to induce a disorganized 
lymphatic phenotype we ablated endogenous macrophages using clodronate-
containing liposomes post-establishment of 4T1.2 tumors. Endogenous 
macrophages were reconstituted post-clodronate treatment with non-educated bone 
marrow macrophages (BMM) or tumor-educated BMM for 48 hours (Figure 2 Di). 
The extent of lymphatic disorganization in the 4T1.2 primary tumors was greater 
after reconstitution with endogenous tumor-educated BMM compared to non-
educated BMM (0.333 ± 0.3 to 2 ± 0.29; Figure 2 Dii, iii). These results demonstrate 
that the presence of tumor-associated macrophages results in a disorganized 
lymphatic vasculature around the primary tumor, that the extent of disorganization is 
related to overall macrophage levels and that this occurs at an early time point in 
tumor development (day 10-14). 
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To investigate how tumor-associated macrophages affect lymphatic endothelia we 
added endogenous macrophages to monolayers of primary LECs isolated from 
BALB/c mice (Figure 2 E). Primary lymphatic endothelial cells had a mean spread 
area of 1132m2 ± 247.9 which reduced slightly to 808.6 m2 ± 185.9 after addition 
of endogenous uneducated macrophages but dramatically reduced to 324.1 m2 ± 
76.43 with tumor-educated macrophages and 473.7 m2 ± 92.8  with ex vivo tumor-
associated macrophages (CD45+Ly6G-CD31-CD11b+). Similar LEC contraction 
occurred when the murine lymphatic endothelial cell line, SV-LECs (Ando et al., 
2005) were grown as a monolayer and endogenous macrophages (SI 1 D) or 
RAW264.7 macrophages added (Figure 2 Fi). SV-LEC contraction occurred with 
area reducing from 835.9 m2 ± 72.32 to 380.5m2 ± 40.82 and 632.5 m2 ± 83.0 to 
82.67m2 ± 14.38 respectively. In addition area of SV-LECs was quantified with and 
without contact with RAW264.7 macrophages. SV-LEC contraction was only 
observed when direct contact between the 2 cell types occurred (436.4 m2 ± 63.3 to 
116.2 m2 ± 34.6) (Figure 2 Fii). Collectively our evidence suggests direct contact 
between tumor-associated macrophages and lymphatic endothelial cells is required 
for contraction events to occur. 
RhoA regulates many events in blood vessel-specific endothelial cells during 
angiogenesis such as motility, proliferation and permeability (Bryan et al., 2010). We 
sought to test whether RhoA regulates contraction events observed in LECs. SV-
LECs were transiently transfected with the GFP- and mRFP-expressing RhoA 
Raichu biosensor (Heasman et al., 2010, Makrogianneli et al., 2009, Yoshizaki et al., 
2003) that allows measurement of the fluorescent lifetime decay (Tau) when FRET 
occurs between the GFP and mRFP upon RhoA activation. After SV-LEC 
transfection, non-educated or tumor-educated endogenous macrophages were 
added to SV-LECs for 24 h. The fluorescence lifetime of the Raichu probe 
(expressed exclusively in the SV-LECs) was measured using multiphoton 
microscopy. SV-LEC co-culture with tumor-educated macrophages led to a reduction 
in donor fluorescent lifetime (Tau) of the biosensor from 1.797 ns ± 0.0252 to 1.622 
ns ± 0.0338, indicating increase in FRET between the GFP and RFP terminal 
fluorophores and consequently an increase in RhoA activity (Figure 2 G). No change 
in Tau was observed when SV-LECs were co-cultured with non-educated 
endogenous macrophages (Figure 2 G ii). These results demonstrate RhoA activity 
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increases during LEC contraction and that this only occures in the presence of 
tumor-educated macrophages in contact with lymphatic endothelia. 
 
Lymphatic endothelial cell contraction is dependent on TGFβ1 release from tumor-
educated macrophages 
TGFβ receptor ligation in fibroblasts results in RhoA activation (Fleming et al., 2009). 
We investigated release of active TGFβ1 and TGFβ2 isoforms from non-educated 
and tumor-educated macrophages by ELISA (Figure 3 A). TGFβ1 levels increased 
from 2600 pg to 4400 pg in tumor-educated endogenous macrophages (increase in 
optical absorbance at 450 nm from 1.286 ± 0.07119 to 2.585 ± 0.1077). In contrast 
TGFβ2 levels were not significantly changed. While TGFβis present throughout the 
tumor microenvironment, membrane-bound TGFβ can have a potent effect on 
downstream signaling though increasing the concentration gradient of this molecule 
(Savage et al., 2008). Our data showed 4T1.2 education of endogenous 
macrophages significantly increased the levels of plasma membrane bound TGFβ1 
(Figure SI 2 A) allowing stringent spatial control of downstream signaling events. 
To test the hypothesis that macrophage-released TGFβ1 was responsible for LEC 
contraction we investigated the effect of a TGFβ-receptor inhibitor, SB-431542 
(Inman et al., 2002) (Figure SI 2 B). As expected, RAW264.7 macrophages alone 
induced LEC contraction (950.6 m2 ± 129.9 to 335.8 m2 ± 38.23); however this did 
not occur in the presence of SB-431542 or when TGFβ1 or β4 integrin were 
transiently knocked down in RAW264.7 macrophages, demonstrating that the 
presence of β4 integrin and TGFβ in macrophages or TGFβ receptor ligation on 
LECs was sufficient to prevent contraction (Figure 3 B and SI 2 C & D). 
The role of macrophage-released TGFβ1 on lymphovascular disorganization was 
investigated in vivo. A stable knockdown of TGFβ1 was generated in RAW264.7 
macrophages using lentiviral shRNA (Figure SI 2 E). Similar to our previous in vivo 
studies, macrophages were administered intravenously throughout tumor 
development. After 2 weeks growth, tissue sections were stained for Lyve1 and 
podoplanin. The extent of lymphatic disorganization in tumors with RAW264.7-
TGFβ1 knockdown compared to RAW264.7-NTC was blindly scored in 
Lyve1/podoplanin stained tissues as before. Our results show that absence of 
TGFβ1 in RAW264.7 macrophages was sufficient to significantly decrease extent of 
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lymphatic disorganization observed compared to RAW264.7-NTC macrophages (1.8 
± 0.16 to 1.1 ± 0.18) (Figure 3 C) and that these changes were evident at an early 
time-point.  
To functionally associate macrophage-released TGFβ1 to structural changes in the 
lymphatic endothelium in vivo we quantified levels of phospho-myosin light chain 
(pMLC) in LECs adjacent to macrophages. Since RhoA activity is high in contracting 
LEC and active RhoA phosphorylates MLC, pMLC can be used as a read-out of LEC 
contractility in cells proximal to lymphatic-associated macrophages. We observed 
that when mice were injected with RAW264.7-TGFβ1 knockdown compared to 
RAW264.7-NTC, there was significant reduction in pMLC levels in lymphatic 
vasculature adjacent to RAW264.7 macrophages when TGFβ1 was absent (1.97 
x106 ± 401151 to 6.56 x105 ± 187133) (Figure 3 D). 
 
TGFβ1 controls β4 clustering at the macrophage plasma membrane 
We studied the effect of TGFβ1 on the phenotypic functionality of macrophages by 
quantifying spreading response of macrophages. There was clear reduction in cell 
spreading when TGFβ1 was knocked down in RAW264.7 macrophages compared to 
the non-targeted control counterpart (235.2 m2 ± 41.06 to 91.91 m2 ± 11.62) 
(Figure 3 E). To understand how TGFβ1 could control macrophage spreading we 
investigated the effect of TGFβ1 on β4 expression. Since integrins can be 
constitutively expressed on the cell surface we sought to study the plasma 
membrane distribution of β4 integrin using structured illumination microscopy in 
RAW264.7-TGFb1shRNA versus RAW264.7-NTC. Our results clearly show that 
while there may be small differences in the overall amount of β4 integrin expressed 
on the cell surface (SI 3 A & B), the size of integrin clusters which can form firm 
adhesive contact with integrin ligand are significantly reduced when TGFβ1 is absent 
(1.97m2 ± 0.12 to 1.559m2 ± 0.0.07; Fig 3 Fi and ii). These results collectively 
indicate that TGFβ1 has both a paracrine role in controlling the lymphatic 
endothelium and an autocrine role in regulating β4 activity in tumor-educated 
macrophages. 
 
β4 integrin+ macrophages and lymphatic remodeling are associated with TGFβ 
signaling and adverse outcome in TNBC patients 
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To establish that human macrophages express ITGB4 RNA (β4 integrin) we 
performed an analysis of a compendium of data composed of macrophages from in 
vitro and in vivo data sets. We observed that ITGB4 is expressed in both human and 
mouse total macrophages (Figure 4 A & SI 4 A). From the same compendium a 
correlation between ITGB4 expression and signaling downstream of TGFβ1 was 
established (Figure 4 B). Single-cell transcriptome analysis of non-tumor cells 
isolated from primary breast tumors revealed that TAMs expressed high levels of 
ITGB4 compared to other non-tumor cells within the tumor microenvironment (Figure 
4 C). To identify patients that may have enrichment of macrophages capable of 
lymphovascular remodeling we used a gene signature containing genes enriched in 
Tie2 expressing macrophages (TEMs) (Pucci et al., 2009) in a cohort of 122 TNBC 
gene expression patterns (Gazinska et al., 2013). We plotted the activation score of 
the TEM gene signature against the TGFβ signaling pathway for each tumor, and 
observed enrichment of patients with distant metastasis when both of these gene 
signatures were present in the primary tumor (Fig 4D). Kaplan-Meier plots also 
showed a significant reduction in distant metastasis free survival (DMFS) in patients 
classified as having a high TEM/TGFβactivation score (Figure 4E). To investigate 
the presence of lymphatic-associated macrophages in breast cancer patients, 
samples from 20 patients were used. Of these patients, 10 were previously 
characterized as having lymphatic vessel invasion (LVI) and the remaining 10 did not 
have LVI. To assess macrophage localization with respect to lymphatic vasculature, 
we dual stained sections with an antibody against CD14 and podoplanin (Figure 4F). 
The sections were scored for presence of CD14+ macrophages within or proximal to 
lymphatic vasculature. In our cohort of 20 patients, all samples exhibited some 
degree of CD14 and podoplanin positivity. Six cases (30%) had macrophages 
associated with lymphatic vessels and of these, 4 were shown to be positive for LVI. 
In this small study, our results suggests that 67% of patients with lymphatic-
associated macrophages also have LVI. In a separate small patient cohort (8 
patients), we demonstrated CD68+ macrophages expressing β4 integrin (ITGB4) in 
close proximity to podoplanin+ vessels using consecutive paraffin-embedded 
sections (Figure 4 G&H). We quantified CD68+ITGB4+ macrophages per mm2 and 
saw an association between CD68+ITGB4+ macrophage score and lymph node 
positivity in individual patients (SI 4 B). Future studies will endeavor to repeat this 
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small study in a larger patient cohort to investigate whether this relationship is 
statistically significant. The combination of our data suggests that β4 integrin-
expressing lymphovascular macrophages may be driving LVI and subsequent 
metastasis to lymph nodes via the lymphatic remodeling signaling cascade. 
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DISCUSSION 
This study demonstrates how crosstalk between a previously unreported tumor-
infiltrating myeloid subpopulation and existing lymphatic vasculature can promote 
metastasis through quantifiable architectural changes in lymphatic vessels. We 
identified a population of β4 integrin-expressing macrophages that drive lymphatic 
remodeling through TGFβ signaling and are associated with adverse pathological 
response in TNBC patients.  
Our study uses both endogenous bone marrow macrophages and the RAW264.7 
macrophage cell line, which is strain-matched to the lymphotropic tumor cell line, 
4T1.2. Through intravital imaging and ex vivo tissue analysis, our TNBC model allows 
us to probe the relationship between the tumor lymphatic vasculature and 
macrophages in vivo and directly translate these phenotypic observations into in vitro 
assays for mechanistic studies. We then directly assess the prognostic significance of 
the key molecules in the lymphatic signaling cascade in predicting adverse 
pathological outcome for a cohort of TNBC patients. In breast cancer samples 
previously characterized for LVI we identify lymphatic-associated macrophages in 
approximately a third of samples and show that LVI was present in the majority of 
these cases. We identify 6β4-expressing macrophages proximal to lymphatic 
endothelium in breast cancer samples, and demonstrate that in patients with a larger 
6β4-expressing macrophage infiltrate, there is a trend towards sentinel lymph node 
metastasis. Our data suggest that 6β4-expressing macrophages may drive 
metastasis via the lymphovascular route in human breast cancer.  
Our study reveals that macrophages are retained in lymphatic endothelium in a 
TNBC model through upregulation of β4 integrin on tumor-educated macrophages. 
While the adhesion receptor 6β4 integrin is ubiquitously expressed in early breast 
cancer (Diaz et al., 2005), transcriptome analysis of breast cancer patient samples 
revealed a correlation between expression levels and prognosis (Lu et al., 2008). 
Through analysis of β4 integrin at transcriptome and protein level we demonstrate a 
population of endogenous macrophages that express β4 integrin and are adherent to 
laminin-5 in lymphovascular areas. Collectively our data suggest that β4 integrin acts 
to ensure that tumor-infiltrating macrophages are in a prime location for sustained 
interaction with lymphatic endothelial cells.  
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We have defined dual functionality of TGFβ where it can affect signaling within tumor-
associated macrophages and LECs. Firstly, we show that TGFβ1 is required for 6β4 
integrin clustering at the macrophage plasma membrane. Integrin clustering can 
positively regulate levels of cell adhesion rapidly in response to soluble stimuli (Hynes, 
2002). TGFβ has previously been demonstrated to control 6β1 and 6β4 integrin 
clustering in HER2-overexpressing mammary tumor cells (Wang et al., 2009). Here 
we describe TGFβ1 dependent β4 integrin clustering in macrophages which control 
the macrophage spreading response necessary for TAM adhesion at the site of 
lymphatic vasculature. 
Secondly, TGFβ1 acts in a paracrine manner to activate RhoA in LECs lining the 
lymphatic vessel demonstrated through RAICHU-FLIM technology (Heasman et al., 
2010, Makrogianneli et al., 2009, Vega et al., 2011). Our study shows that signaling 
within LECs in contact with TAMs drives LEC contraction, which correlates to gross 
architectural changes and hyperpermeability of the lymphatic vessel network that 
could actively facilitate metastasis. We have previously demonstrated the activation of 
RhoGTPases by integrin signaling in cis (on the immune cells that are triggered by 
adhesion processes (Makrogianneli et al., 2009, Carlin et al., 2011, Heasman et al., 
2010, Ramsay et al., 2013). Our current study indicates this phenomenon can also 
occur in trans i.e. activation of RhoGTPases in the endothelial cells that are contacted 
by the adherent macrophages, through the expression of factors such as TGFβ1.The 
role of macrophage-released TGFβ1 in vivo is shown to have an effect on the RhoA 
pathway in proximal LEC and a concomitant role in lymphovasculature 
disorganization. 
In summary, this study identifies an alternative macrophage-mediated signaling 
pathway involved in promotion of lymphatic metastasis. Our work emphasizes the 
importance in considering crosstalk between macrophages and the lymphatic vessel 
network in TNBC, where aggressive tumor growth and rapid metastasis often mean a 
poor outcome. We hope this study will guide future endeavors to focus on 
therapeutically targeting the lymphatic remodeling signaling cascade in TNBC disease 
progression. 
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Titles and legends to figures 
Figure 1.  Lymphovascular macrophages in TNBC mouse models are retained 
through binding of β4 integrin to laminin-5. Tumor sections from 4T1.2 (A) and  
BLG-Cre;Brca1f/f,p53+/-  (B) stained with F4/80-FITC, podoplanin-AF555 and Tie2 -
Cy5 conjugated antibody. F4/80+Tie2+ macrophages within podoplanin+ areas 
versus those in other areas quantified per field of view (FOV). Vessel lumen outlined, 
arrow shows a macrophage within a podoplanin+ area. Images acquired with x40 air 
objective, scale bar 100 m (main image), 25 m (zoomed inset). (C) Array-derived 
expression profile of β4-integrin (Itgb4) across samples. Barplot shows log2 fold-
change of normalized expression value for β4 integrin (ratio of the median value of 
probe in BMM samples). (D) Day 12 4T1.2 tumors were disaggregated. Tie2 and β4 
integrin FMO controls shown in 2 left panels. Right dot plot and histogram depict β4 
integrin expressing macrophages from representative 4T1.2 tumor (n = 8). (E) BMM 
co-cultured alone/with 4T1.2-GFP cells plated on laminin-5. % adherent cells 
quantified in triplicate (n = 2). 4T1.2 tumor sections stained with (F) laminin-5-
Dylight488 and podoplanin-AF555 (G) Lyve1-Cy3; F4/80-FITC and β4 integrin-cy; 
inset shows F4/80+β4 integrin+ macrophages around lymphatic endothelium. (H) 
Stained sections (Lyve1-Cy3 and β4 integrin-Cy5) imaged using a custom-built 
microscope (x20 air obj). Area of distinct β4 integrin and Lyve1 within lymphatic 
vessel (white arrow) and area of close contact between β4 integrin and Lyve1 (blue 
arrow). Scale bar, 50 µm (main panels), 25 µm in (inset). 
Figure 2. TAMs drive dilated, hyperpermeable and disorganized lymphatic 
architecture through LEC RhoA activation. (A) i) Mouse with mCherry-tagged 
4T1.2 tumor and implanted mammary imaging window (MIW) at day 10-14. ii) 
Lymphatic vessels (green) surrounding tumor (red, left panel; lymphatic vessels 
(green) distal to main tumor bulk (red, middle panel); lymphatic vessel (green) with 
tumor cells (red) within vessel (right panel). Scale bar, 100 m. (B) 4T1.2 tumor-
bearing mice treated with PBS or RAW264.7 macrophages over 3 weeks. 1% Evans 
Blue dye stained lymphatics in vivo. Lymphatic permeability calculated as optical 
density per gram tumor. Data represent means ± SEM, significance determined 
using unpaired t-tests (**p<0.01). (C) i) Lymphatic vessels within tumors from mice 
treated with PBS or RAW264.7 macrophages stained with Lyve1-Cy3 or podoplanin-
AF555 (red), and blindly scored for disorganization. Scale bar, 50 µm ii) Four FOV in 
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4 PBS-treated and 4 RAW264.7 macrophage-treated tumor samples scored blindly 
for disorganization. Data represent means ± SD, significance determined using 
unpaired t-tests (***p<0.001) (D) i) Timeline depicting clodronate-containing liposome 
protocol. ii) Tumor sections from clodronate-treated mice reconstituted with PBS, 
BMM or BMM stained with Lyve1-Cy3 or podoplanin-AF555 (red). Lymphatic 
disorganization within tumors from 6 mice quantified from > 3 FOV per mouse from 
Lyve1 stained sections. Data represent means ± SD, significance determined using 
unpaired t-tests (**p<0.01). (E) Primary LEC cultured alone, with BMM, tumor- 
eBMM or TAM. LEC stained with podoplanin-AF555 and macrophages stained with 
F4/80-FITC. Confocal microscopy (x40 air obj) used to quantify area of LEC from 3 
FOV (n = 2). Scale bar, 10 µm. (F) i&ii) Monolayer of SV-LECs (cell tracker green 
(CMFDA)) with RAW264.7 macrophages (cell tracker orange (CMTMR)) after 24 h. 
Area of SV-LECs measured using ImageJ software. Data represent means ± SEM; 
significance determined using unpaired t-tests (**p<0.01). Scale bar, 25 µm. (G)i) 
SV-LECs transfected with RhoA Raichu biosensor (Raichu R/G) or RhoA-GFP as a 
control. Transfected SV-LECs cultured alone or with BMM/eBMMfor 24 h. ii) 
Multiphoton microscopy used to determine fluorescence lifetime (Tau (ns)) of SV-
LECs transfected with RhoA-GFP or RhoA Raichu biosensor. Data represent means 
± SD, significance determined using unpaired t-tests (**p<0.01). 
Figure 3. Macrophage-expressed TGFβ1 regulates β4 integrin clustering on the 
macrophage plasma membrane and is required for LEC contraction. (A) Bone 
marrow macrophages cultured alone (BMM) or with 4T1.2 cells (BMM co-culture). 
Supernatants probed for i) TGFβ1 and ii) TGFβ2 by ELISA. Data represent means ± 
SD and significance determined using unpaired t-tests (***p<0.001). (B) SV-LECs 
grown as monolayers. Tumor-educated RAW264.7 macrophages (eRAW) added 
plus DMSO control /10 µM SB-431542. After 24 h, SV-LEC areas were quantified. 
Data represent means ± SD, significance determined using unpaired t-tests 
(****p<0.0001). (C) Tumor-bearing mice injected with RAW264.7-NTC or RAW264.7-
TGFβ1 knockdown until d 14. Tumors sections stained with podoplainin-AF555 or 
Lyve1-Cy3 and Lyve1+ vessels blindly scored for lymphatic disorganization 
(*p<0.05). Scale bar, 50m. (D) Tumor-bearing mice injected with RAW264.7-NTC 
or RAW264.7-TGFβ1 until d 21. Tumor sections were stained with F4/80-FITC, 
pMLC (and Rabbit-Cy3 secondary antibody) and podoplanin-Cy5. F4/80+ cells within 
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podoplanin+ regions were identified and a 65 m2 ROI was identified (white circles) 
where fluorescence intensity of pMLC signal was quantified. Scale bar, 50 m (4 
FOV from n = 2 tumors from each condition). Data represent means ± SD, 
significance determined using unpaired t-tests (**p<0.01). (E) RAW264.7-NTC or 
RAW264.7-TGFβ1 macrophages area measured by confocal microscopy. Data 
represent means ± SD, significance determined using unpaired t-tests (**p<0.01). (F) 
RAW264.7-NTC or RAW264.7-TGFβ1 stained with anti-β4 integrin-AF647 and 
imaged using structured illumination microscopy (Nikon x100 oil objective). Focal 
adhesion area determined using ImageJ on thresholded images. Data represent 
means ± SD, significance determined using unpaired t-tests (**p<0.01). Scale bar, 
10µm; 1µm (inset). 
Figure 4. β4 integrin-expressing macrophages and lymphatic remodeling 
associated with TGFβ signaling and adverse outcome in TNBC patients. (A) 
ITGB4 expression in human macrophages. Y-axis indicates normalized expression 
on log2 scale. Red line indicates median expression of all genes. Raw gene counts 
obtained from the ARCHS4 database. (B) Correlation between ITGB4 expression 
and enrichment of TGFβsignaling in human macrophages (Spearman rho = 0.26; 
p<0.001. X-axis indicates normalized expression on the log2 scale. Y-axis indicates 
ssGSEA enrichment scores computed for the TGFβ hallmark gene set obtained from 
MSigDB data base. Red curve indicates loess fit. Association strength quantified 
using Spearman correlation coefficient. Raw gene counts obtained from the 
ARCHS4 database. (C) Expression of ITGB4 in scRNAseq data of primary breast 
cancer (GSE75688). Data reported as log2(TPM+1). (D) Activation score of TEM 
gene signature and TGFβ signaling shown. Red and green dots indicate TNBC 
with/without distant metastasis respectively. Enrichment of TNBC with distant 
metastasis in the top right quadrant established by hypergeometric testing. (E) 
Kaplan-Meier survival curves showing distant metastasis free survival in TNBC. 
Stratification based on samples with high TGFβ signaling and TEM gene signature 
activation score classified as “high TEM/TGFβ signature” versus the remainder (“low 
TEM/TGFβ signature”). (F) Representative breast cancer section (from n=20) 
stained with CD14 (red) and podoplanin (brown). Scale bar, 100 µm. Zoomed inset 
demonstrates CD14+ macrophages associated with podoplanin+ lymphatic 
vasculature (black arrows). Tissues selected from 8 patients with/without lymph node 
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positivity. Consecutive sections were stained singly for podoplanin 
lymphovasculature, or doubly using pan-macrophage marker, CD68 and anti-b4 
integrin antibody. (G) Double stained macrophages per mm2 shown with patient 
clinical details (LVI and lymph node positivity). CD68+ITGB4+ macrophages 
indicated in upper right panels (red arrows) and CD68 and ITGB4 staining shown 
below as 2 single panels, CD68+ITGB4+ macrophages indicated with red arrow. 
Podoplanin+ vessels shown in upper left images (black arrows). Scale bar, 20 µm.  
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STAR METHODS 
Contact for reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to the 
Lead Contact, Tony Ng (tony.ng@kcl.ac.uk) 
For a detailed description of the experimental procedures please see 
supplementary information. 
Experimental Model and Subject Details 
Tissue culture 
Bone marrow macrophages: Monocytes were isolated from female BALB/c mice 
femurs and cultured in mCSF-1 for 5 d. 
Cell lines: All cell lines were tested as mycoplasma negative and authenticated by 
IDEXX Laboratories Ltd, UK. 
Tumor-bearing mice 
4T1.2 : BALB/c immune-competent mice were 6–8 weeks of age and maintained 
under pathogen-free conditions. Tumors were established by injection of 1x106 4T1.2 
cells into the mammary fat pad.  
BLG-Cre;Brca1f/f,p53+/-: Mammary tumor chunks (approximately 0.2cm3) dissected 
from BLG-Cre;Brca1f/f,p53+/- mice (Molyneux et al., 2010) were transplanted 
orthotopically into mammary fat pads of recipient 5-week old C57BL6J mice. Tumors 
were grown for 4-8 weeks before mice were culled and tumor tissues harvested. 
Human breast cancer samples 
Paraffin embedded samples (n=20) (KHP Cancer Biobank Molecular Taxonomy of 
Breast Cancer International Consortium (METABRIC) dataset cohort) were used. 
Ten patients were previously characterized as having lymphatic vessel invasion (LVI) 
and the remaining 10 did not have LVI. Please see SI for details on staining. 
Study approval 
All experiments were performed in accordance with the local ethical review panel, 
the UK Home Office Animals Scientific Procedures Act, 1986 and the UKCCCR 
guidelines.  
Method Details 
RAW264.7 macrophage treatment 
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Tumor-bearing mice were injected with 100l PBS or 1x106 RAW264.7 macrophages 
starting on the second day after tumor inoculation and repeated every 2 days until the 
end of the experiment.  
Clodronate treatment 
Endogenous macrophages were ablated using clodronate-containing liposomes 
(Weisser et al., 2012). 
Immunofluorescence  
Tissue sections were fixed with 4% paraformaldehyde (PFA), blocked in 5% BSA 
followed by staining. Hoechst-33342 (0.1 µg/ml) was used for nuclear staining and 
samples mounted using Mowiol (with DABCO). Image acquisition by confocal 
microscopy was performed using a Nikon Eclipse Ni-E Upright. Image acquisition was 
conducted using NIS Elements C software and analyzed using Image J software. 
Image acquisition and analysis for colocalization studies in tissue 
Cy3 and AF647 dyes were imaged before and after photobleaching using  (x20 
0.75NA air objective, Nikon) and a cooled CCD detector (Hamamatsu ORCA-03G, 
1024 x 1024) with respective integration time of 100 ms and 1000 ms. Dyes were 
photobleached using a mode-locked Titanium Sapphire Laser (Coherent, 
Chameleon Ultra 2) tuned at 730 nm with pulse duration of about 200 fs, a repetition 
rate of 80 MHz and average laser power on the sample of 30 mW. To measure the 
relative level of β4 integrin expression within the lymphovasculature compared with 
the rest of the tissue, we measured average AF647 intensity within 
lymphovasculature areas (high Cy3 intensity) normalized by the average AF647 
intensity outside lymphovasculature areas (low Cy3 intensity). 
Structured Illumination Microscopy (SIM) 
RAW264.7-NTC or RAW264.7-TGFβ1 KD were stained with rat anti-β4 integrin 
antibody and anti-rat AF647 antibody. Image acquisition by SIM was performed using 
Nikon N-SIM microscope equipped with a 640nm laser, a Andor iXon Ultra 897 
EMCCD camera and a 100x 1.49NA oil immersion objective. Images were analyzed 
using ImageJ software. 
Mammary imaging window implantation and intravital microscopy  
Mammary Imaging Window (MIW) surgery was performed 10-14 days after tumor 
innoculation (Kedrin et al., 2008). Images shown are representative of a minimum of 
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5 independent experiments.For imaging lymphatic vasculature, mice were injected 
subcutaneously at the tail base with 50 l 76kDa dextran-fluorescein or dextran-Texas 
red 15 min prior to imaging. Mice were imaged for a maximum period of 4 h per day 
using a x20 air objective. All post-hoc image processing and image reconstructions 
were done using Image J software.  
Lymphatic vessel permeability  
Tumor-bearing mice were injected subcutaneously at the tail base with 1% Evans Blue 
dye. After 30 min the mice were culled and the tumors incubated in formamide 
overnight at 55oC. Optical density of formamide was read at 620nm and quantification 
of lymphatic permeability was given as OD per g tumor.  
Adhesion assay 
Laminin-5 was plated onto 96 well plates overnight at 4oC and non-specific interactions 
blocked with BSA. Macrophages (5×106/ml) were labeled with 1 μM 2′,7′-bis-(2-
carboxyethyl)-5-(and-6)-carboxyfluorescein-acetoxymethyl ester (BCECF) for 30 min 
at room temperature. 100μl of cells (1×106/ml) were added at 37oC, plates washed, 
and adhering macrophages quantified using a fluorescence microtiter plate reader. 
Lymphatic endothelial cell contraction  
SV-LEC cells or primary lymphatic endothelial cells were grown as a monolayer. On 
day 3 LECs and macrophages were stained for 30min at 37oC using 1g/ml CMTMR 
or CMFDA respectively. Macrophages were added to SV-LEC monolayers overnight. 
Confocal images of the co-culture and the area around individual SV-LECs was 
calculated using ImageJ software. 
RhoA biosensor  
SV-LECs were transiently transfected with the Raichu RhoA biosensor (Yoshizaki et 
al., 2003). The biosensor was modified to express GFP and mRFP (Makrogianneli et 
al., 2009). Multiphoton time-correlated single photon counting FLIM was performed to 
quantify RhoA biosensor FRET Fluorescence excitation was provided by a Fianium 
laser, which generates optical pulses with a duration of 40 ps at a repetition rate of 80 
MHz. For the imaging of Raichu-transfected SV-LECs, multi-photon excitation was 
employed using a solid-state pumped (8-W Verdi; Coherent), femtosecond self-mode 
locked Ti:Sapphire (Mira; Coherent) laser system (Peter et al., 2005, Barber et al., 
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2009). Imaging data comprised of 256 x 256 pixel resolution and 256 time channels. 
The fluorescence lifetime was calculated as described (Barber et al., 2013). 
TGFβ1 stable knockdown in RAW264.7 macrophages 
Stable TGFβ1 knockdown RAW 264.7 macrophage lines were generated by lentiviral 
transduction using the pGIPZ system (Open Biosystems). Viral packaging was 
performed by transiently transfecting HEK293T cells with the pGIPZ shRNA transfer 
vector and the accessory plasmids pCMV-dR8.91 and pMD2G. Stable cell lines were 
established using three different shRNA lentiviral vectors. RAW 264.7 macrophages 
were cultured in puromycin (1 µg/ml) to enable the selection of successfully 
transduced cells and efficacy of knockdown was assessed by western blotting.  
FACS analysis 
RAW264.7 cell lines (TGFβ1-knockdown or NTC) were stained with a Live-Dead 
Yellow dye followed by staining with a primary rat anti-β4 integrin antibody and anti-
rat AF647-conjugated secondary antibody.  
Tumors were disaggregated with Collagenase (Sigma UK) and DNase I (Applichem, 
UK) before staining with Live-Dead Yellow, CD45-APC Cy7, Ly6G-Biotin + 
Streptavidin AF488, CD11b-eFluor450, Tie-2 PE β4 integrin-BV711 and CD31 
PerCPCy5.5. Cells were fixed with 1% PFA and analysed in a FACS Canto II (BD 
Biosciences) cytometer. Data analysed using FlowJo software (TreeStar Inc., 
Ashland, OR, USA). 
Human tissue staining 
Sections were stained using anti-CD14/anti-podoplanin using Ventana Benchmark 
Ultra and Ultra view DAB and Alkaline Phosphatase detection systems. Sections 
were assessed independently by two histopathologists and scored for CD14+ 
macrophages within or proximal to lymphatic vasculature. 
Alternatively, using consecutive sections the first section was stained with anti-
podoplanin and the second section stained with anti-ITGB4 anti-CD68. All sections 
were stained with DAB+ substrate/chromagen. All incubations were at room 
temperature. 
The slides were scanned in the Hamamatsu NanoZoomer S210 Digital slide 
scanner. The image analysis was performed on the whole section with the color 
deconvolution module and the positive pixel algorithm from QuPath image analysis 
software.  
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Quantification and Statistical Analysis 
Gene expression microarray analysis 
RNA was extracted from macrophage cell cultures and profiled using Affymetrix 
Mouse Gene 1.0 ST arrays. Differential expression between conditions was 
estimated by fitting a linear model and performing empirical Bayes moderated t-tests 
using the package ‘limma’ (v3.22.4) (Ritchie et al., 2015). The expression score for a 
specific gene in each sample is defined as the weighted sum of gene-standardized 
(Z-score) expression values, with weights +1/-1 according to relative increase or 
decrease in BMM + 4T1.2 compared with BMM. 
Analysis of gene signatures 
To establish ITGB4 expression and assess association between ITGB4 expression 
and activation of the TGFβ signaling in macrophages, processed gene counts were 
obtained from the ARCHS4 database (Lachmann et al., 2018) and further normalized 
for downstream analyses. Enrichment of TGFβ signaling was computed using the 
ssGSEA method (Barbie et al., 2009) as implemented in the GSVA package 
from Bioconductor. 
False zero expression due to dropout events in scRNA-seq data was corrected using 
the scImpute algorithm as previously described (Li and Li, 2018). scRNAseq data is 
reported as log2(TPM+1). 
Macrophage-mediated vascular remodeling pathway signature (Pucci et al., 2009) 
was converted to a human gene list using Biomart ID conversion (Ensembl Genes 84// 
mus musculus genes GRCm38.p4). TGFβ (KEGG) gene signature was derived from 
(MSigDB). Gene signature activity was calculated using a weighted average sum over 
all genes for each tumor. Pearson’s correlation between the activation scores was 
reported. Hypergeometric testing was used to establish the significance of overlap 
between TNBC with distant metastasis (DM) on those of dual high activation scores. 
Kaplan-Meier plots were generated for each data set to provide a visualization of 
survival stratification. 
All other statistical analysis is described in the text and legends and was preformed 
using Prism software (GraphPad). P values less than 0.05 were considered 
significant.  The statistical test used is indicated in the figure legends and the 
significance of findings is indicated in the figures.  
27 
 
Data and software availability: Experiment ArrayExpress accession: E-MTAB-
4064.
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rat monoclonal anti-Lyve1  Novus Biologicals #NB-600-1008 
Rabbit polyclonal anti-Tie2 (C-20) Santa Cruz #sc-324 
Rabbit polyclonal phospho-Smad2/3 (D27F4) Cell Signaling #8828 
Mouse monoclonal anti-ITGB4 Abcam #ab29042 
Mouse monoclonal anti-CD68 antibody Ventana Cell 
Marque 
#168M 
Mouse monoclonal anti-CD14 (EPR3653)
   
Ventana Cell 
Marque 
#114R 
Mouse monoclonal anti-podoplanin (D2-40) Ventana Cell 
Marque 
#332M 
Rat monoclonal anti-CD45-APC-Cy7 Biolegend #103115 
Rat monoclonal Ly6G-Biotin  Biolegend #127603 
Streptavidin AF488 Biolegend #405235 
Rat monoclonal CD11b-eFluor450 ThermoFisher 
Scientific 
#48-0112-82 
Rat monoclonal Tie-2 PE Biolegend #124007 
Rat monoclonal β4 integrin-BV711 BDBiosciences #744154 
CD31 PerCPCy5.5 Biolegend #102419 
Rat monoclonal anti-F4/80-FITC (clone BM8) Abcam #Ab60348 
 Rabbit polyclonal anti-laminin-5 Abcam #Ab14509 
Rabbit polycloncal Anti-Phospho myson light 
chain (Ser19) 
Cell Signaling #3671 
Mouse monoclonal anti-podoplanin antibody Santa Cruz  #sc-166906 
Rabbit polyclonal anti-TGFb1 antibody  Proteintech #11522-1-AP 
Biological Samples   
Key Resource Table
Breast cancer tumor tissues (paraffin-
embedded) 
King’s College 
London breast 
cancer biobank 
Team lead – Dr 
Cheryl Gillet 
4T1.2 tumor tissues (frozen) King’s College 
London 
Dr Rachel Evans 
BLG-Cre;Brca1f/f,p53+/- tumor tissues (frozen) King’s College 
London 
Dr Rebecca 
Marlow 
Chemicals, Peptides, and Recombinant Proteins 
Cell trackerTM red (CMTMR) and Cell trackerTM 
green (CMFDA) 
Life Technologies #C34552, C2925 
Murine CSF1 Sigma #M9170 
Human recombinant laminin-5 Novus Biologicals #H00003911 
Clodronate and PBS liposomes Liposoma 
Technology 
#CP-005-005 
2′,7′-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein-acetoxymethyl ester 
(BCECF) 
Thermo Scientific #B1170 
SB-431542 Sigma #S4317 
Evans Blue dye Sigma #E2129 
Formamide Sigma #F9037 
76kDa dextran Texas Red Sigma #R05027 
76kDa dextran fluorescein Santa Cruz #sc-263323 
Critical Commercial Assays 
Murine TGFb1 quantikine ELISA kit R&D Ltd #MB100B 
Murine TGFb2 quantikine ELISA kit R&D Ltd #DB250 
Deposited Data 
Experiment ArrayExpress accession Array Express #E-MTAB-4064. 
Breast Cancer Gene Expression data  Gene Expression 
Omnibus 
#GSE75688 
ARCHS4 database (Lachmann et al., 
2018) 
N/A 
Experimental Models: Cell Lines 
4T1.2 cells derived from female BALB/C 
mouse 
(Lelekakis et al., 
1999) 
N/A 
SV-LEC (derived from male “immortomouse”) (Ando et al., 2005) Gift from Dr 
Steven 
Alexander 
 
Primary LEC from male BALB/C mouse Generon Ltd #BALB5064L 
RAW264.7 derived from male BALB/C mouse ATCC Ltd #ATCC-TIB71 
HEK293T (derived from human fetus) ATCC Ltd #ATCC-CRL-
11268 
Experimental Models: Organisms/Strains 
Female BALB/c mice Charles River N/A 
Female C57Bl6J mice Charles River N/A 
Oligonucleotides 
Raichu RhoA biosensor construct King’s College 
London 
(Heasman et al., 
2010) 
GFP-RhoA construct King’s College 
London 
(Heasman et al., 
2010) 
Software and Algorithms 
TRI2 
https://app.assembla.com/spaces/ATD_TRI/wi
ki 
Gray Laboratories 
Oxford University 
and University 
College London 
Dr Paul Barber 
(Barber et al., 
2013) 
Prism Software  https://www.graph
pad.com/scientific-
software/prism/ 
N/A 
ImageJ (Fiji)  https://imagej.nih.g
ov/ij/ 
N/A 
Colocalisation plugin for ImageJ (within this 
manuscript) 
Dr Fred Festy  
Other 
TGFb1 shRNA (GIPZ) Open Biosystems University 
College London 
library 
ITGB4 shRNA (GIPZ) Open Biosystems University 
College London 
RNA easy minikit Quiagen #74104 
Live/Dead Yellow dye  Invitrogen #L34959 
Affymetrix Mouse Gene 1.0 ST arrays Thermo Scientific #901168 
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Figure S1. Elevated macrophages in tumor-bearing mice increases lymphatic vessel diame-
ter and contact between SV-LEC and endogenous tumor-educated macrophages results in 
LEC contraction, related to Figure 2 
Tile scans representative of whole tumor sections from mice treated with PBS or RAW264.7 mac-
rophages.10 µm fixed sections were stained with (A) Lyve1 antibody and Cy3-conjugated second-
ary antibody or (B) podoplanin-AF594 (red) to allow confocal imaging of lymphatic vasculature i) (x4 
objective, scale bar, 50 µm) (C) The maximum diameter across Lyve1+ vessels was measured in 
image J from at least 4 fields of view from each tumor section from 4 PBS-treated and 4 
RAW264.7-treated mice. (D) Representative images of tumour tissues from mice treated with PBS 
liposomes or clodronate liposomes. F4/80-Cy3 (red) depicts infiltrating macrophages (E) SV-LECs 
were grown as a monolayer on a glass coverslip and stained with CMTMR (red) or CMFDA (green). 
Non-educated and tumor-educated bone marrow macrophages (BMM and eBMM respectively) 
were stained with F4/80-Cy5 (white) and both cell types were stained with Hoescht-33342 (blue).
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Figure S2. Western blot analysis of TGFβ1 knockdown in RAW264.7 cells, related to Figure 3 
(A) Bone marrow macrophages were cocultured alone or with 4T1.2 tumor cells for 5 days on glass cov-
erslips. Cells were fixed with 4% PFA before staining with F4/80-FITC and TGFβ1 and a Cy3 secondary 
antibody and imaging by confocal microscopy. Cell boundary depicted with white dotted line in inset 
image. (B) SV-LECs treated with SB-43142 were analysed by western blot to assess levels of phospho 
Smad2/3 (C) RAW264.7 were transiently transfected with shRNA against β4 integrin or TGFβ1 and ana-
lysed by western blot. (D) Macrophages were cocultured with SV-LECs and the contraction of SV-LECs 
measured (E) RAW264.7 cells were virally transduced with shRNA against TGFβ1 or NTC. (i) Macrophag-
es that were transfected were selected for GFP expression and lysed using an SDS buffer. Lysates were 
run on a reducing gel (4-12% Bis-Tris), blotted onto PVDF and the membranes were probed for TGFβ1 or 
β-tubulin as a loading control. (ii) Supernatants were analysed by ELISA for TGFβ1 levels.
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Figure S3. Endogenous macrophages increase expression of membrane-bound TGFβ1 after 
co-culture with 4T1.2 tumor cell, related to Figure 3 
(A) The fluorescence intensity from F4/80+ cells was quantified (white arrows) and normalized to cell 
area. Scale bar, 10µm. Data represent means ± SD, significance was determined using unpaired 
t-tests (**p<0.01). (B) NTC- and TGFβ1-KD RAW264.7 macrophages were stained with rat anti-β4 
integrin followed by secondary goat anti-rat-AF647 antibody. Expression levels of β4 integrin were 
analyzed by FACS and a representative histogram is depicted (n = 2 independent experiments).
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Figure S4. Expression of ITGB4 in murine macrophages (A) ITGB4 expression in murine mac-
rophages, related to Figure 4 
The y-axis indicates normalized expression on the log2 scale. The red line indicates median expres-
sion of all genes. Raw gene counts were obtained from the ARCHS4 database. (B) CD68+ITGB4+ 
macrophages in lymph node negative versus lymph node positive tissues are shown graphically.
